Medical Necessity Letter (Anti-Obesity Medication)

[Provider Name, Credentials]
[Specialty / Clinic Name]
[Address Line 1]
[Address Line 2]
Phone: [Provider Phone] | Fax: [Provider Fax]
NPI: [Provider NPI]

Date: [Date]

To: [Plan Name] – [Utilization Management / Prior Authorization / Appeals Department]
[Plan Address Line 1]
[Plan Address Line 2]
Fax: [Plan Fax]

RE: Medical Necessity [Request / Appeal] – Anti-Obesity Medication
Patient: [Patient Full Name] | DOB: [Date of Birth] | Member ID: [Member ID]
Requested Medication: [Generic Name (Brand Name)] [Formulation / Route] – [Requested Dose] [Frequency]
PA Case #: [Case Number] | Denial Reference/Date: [Denial Reference and Date] (Include for appeals only)

Dear Reviewer,

Request Summary

Type of Request: [Initial Authorization / Appeal of Denial / Step-Therapy Override]
Label Status: [On-label / Off-label] for pediatric use.
Plan's Denial Rationale: [Brief quote or paraphrase of denial reason] (Include for appeals; this letter addresses each point directly.)
Clinical Justification: [One to two sentences summarizing the medical necessity, referencing attachments by number when relevant]

Patient Clinical Summary

Primary Diagnosis: [Obesity / Severe Obesity] (Pediatric classification per BMI percentile)
Current Severity (measured [Date of Measurement]): Height [Height], Weight [Weight], BMI [BMI value] kg/m², BMI Percentile [Percentile value], Percent of 95th Percentile [% of 95th]
Duration and Trajectory: [One sentence describing duration of obesity and weight trend; reference Attachment # for BMI trajectory table]
Risk Linkage: [Brief statement linking current severity to health risks and/or documented comorbidities]

BMI Trajectory

(Include at least three timepoints over the past 6–12 months when available: pre-intervention baseline, post-lifestyle intervention, and current. If earlier measurements are unavailable, state this explicitly.)

Date	Age	Height	Weight	BMI	BMI Percentile	% of 95th Percentile	Notes
[Date]	[Age]	[Height]	[Weight]	[BMI]	[Percentile]	[% of 95th]	[Pre-intervention baseline]
[Date]	[Age]	[Height]	[Weight]	[BMI]	[Percentile]	[% of 95th]	[During / after lifestyle intervention]
[Date]	[Age]	[Height]	[Weight]	[BMI]	[Percentile]	[% of 95th]	[Current measurement]

(If earlier measurements are unavailable, state: "Earlier BMI data not available in chart.")

Obesity-Related Comorbidities

(List only conditions assessed and documented. For suspected conditions, label as suspected and note planned evaluation. Use person-first language.)

• [Condition Name]: Diagnostic basis: [Values, dates, or test results]. Status: [Controlled / Uncontrolled / Suspected]. Management: [Current treatment or planned evaluation].
• [Condition Name]: Diagnostic basis: [Values, dates, or test results]. Status: [Controlled / Uncontrolled / Suspected]. Management: [Current treatment or planned evaluation].

(If no comorbidities identified: "No obesity-related comorbidities identified to date following evaluation documented in Attachment [#].")

Prior Lifestyle and Behavioral Treatment

(Document only structured, charted interventions.)

• Program/Setting: [Program type and location]
• Components: [Dietary modification, physical activity plan, behavioral strategies, caregiver engagement]
• Timeline: [Start date] – [End date] (Total duration: [Duration])
• Intensity: [Contact hours or visit frequency] with [Disciplines involved]
• Response: [Summary of weight/BMI trajectory during program; reference BMI table]
• Barriers and Supports: [Barriers encountered] addressed with [Supports provided]

Prior Medication Trials

(Include if patient has tried other anti-obesity medications or if step-therapy requirements apply. Omit section if not applicable.)

• [Medication Name]: Dates: [Start–End]; Dose/Titration: [Details]; Response: [Weight/BMI change, appetite, functional impact]; Adverse effects: [If any]; Reason discontinued or not appropriate now: [Reason]
• Contraindications to Alternatives: [Agent name] contraindicated due to [Teratogenicity risk / Psychiatric contraindications / Drug interactions / Age restrictions / Other reason]

Requested Medication and Clinical Rationale

• Medication: [Generic (Brand)] [Formulation/Route]
• Dosing: Start [Starting dose], titrate by [Titration schedule] to [Target dose]; Frequency: [Frequency]; Quantity: [Quantity] with [Number] refills; Duration to reassessment: [Timeframe]
• Adjunctive Treatment: Prescribed as adjunct to reduced-calorie nutrition plan and increased physical activity; ongoing lifestyle treatment continues concurrently under [Discipline/Provider]
• Eligibility: [On-label: Patient age and BMI metrics meet labeled criteria] [Off-label: Explicitly off-label; on-label options not appropriate because (reason); evidence basis in Attachment #; enhanced safety monitoring outlined below]
• Agent Selection Rationale: [Rationale based on comorbidity profile, administration feasibility, prior response/intolerance, and safety considerations]

Safety Assessment

(Mark each as present, absent, or unknown. If family history is unknown, state this and describe the safety plan.)

• Personal/Family History Screen: MTC/MEN2 [Present / Absent / Unknown]; Pancreatitis [Present / Absent / Unknown]; Gallbladder disease [Present / Absent / Unknown]; Severe GI disease [Present / Absent / Unknown]; Glaucoma [Present / Absent / Unknown]; Seizure disorder [Present / Absent / Unknown]; Major depression/suicidality [Present / Absent / Unknown]
• Reproductive Considerations: [Baseline pregnancy test status, contraception counseling, teratogenicity discussion as applicable] (Include for patients of childbearing potential)
• Medication Review: Current medications: [List]. Potential interactions: [Identified interactions or "none identified"]
• Education Provided: Reviewed common adverse effects, warning signs requiring medical attention, when to hold medication, and emergency contact. Patient and caregiver verbalized understanding.

Monitoring and Follow-Up Plan

• Baseline (prior to initiation): Vitals, anthropometrics (height, weight, BMI, BMI percentile, % of 95th percentile); Labs: [Indicated baseline labs]; Mental health screening [if clinically indicated]
• Titration Phase: [Telehealth / Phone] check at [Timeframe] to assess tolerability; visit at [Timeframe] for vitals, side effects, dose adjustment
• Ongoing Monitoring: Visits every [Interval] for growth tracking including linear growth, vitals, side effect review, adherence assessment, lifestyle reinforcement; Labs repeated at [Interval] or per clinical indication
• Care Team: Dosing managed by [Prescribing clinician]; nutrition/behavior monitored by [Dietitian / Behavioral health / Program]; specialty referral to [Specialty] as indicated

Treatment Goals and Continuation Criteria

• Clinical Goals: [Target BMI percentile or % of 95th percentile reduction by timeframe]; [Comorbidity marker improvements]; [Functional goals]
• Reassessment Schedule: Evaluate response at [~3 months] and [~6 months] with documented anthropometrics and comorbidity markers
• Discontinuation Criteria: Inadequate response defined as [Agent-specific stopping rule, e.g., less than X% BMI reduction after Y weeks at maintenance dose], or intolerable adverse effects. Family understands medication will be discontinued if risks outweigh benefits.

Attachments

1. Growth chart / BMI percentile printout (including % of 95th percentile)
2. Recent clinic notes documenting diagnosis and management plan
3. Dietitian / behavioral program notes with attendance summary
4. Laboratory results supporting comorbidities and baseline safety
5. Relevant specialty reports (Include for appeals or if applicable)
6. Current medication and allergy list
7. Denial letter and relevant plan policy excerpt (Include for appeals)
8. Evidence summary or guideline excerpts supporting requested therapy (Include for off-label or appeals)

Closing

Based on [Patient first name]'s documented clinical status and current standards of care for pediatric obesity, the requested anti-obesity medication is medically necessary to reduce health risks and improve outcomes. I am available for peer-to-peer review at the contact information below.

Sincerely,

[Provider Signature]
[Provider Printed Name, Credentials]
NPI: [Provider NPI]
Direct Phone: [Direct Phone] | Secure Fax: [Provider Fax]
Date: [Date]